Índice Bovespa

US Dollar vs BRL

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

REGN Regeneron Pharmaceuticals Inc

993,95

0,00 (0,00%)

Pré-mercado

Última atualização: 05:05:39

Atrasado em 15 minutos

Biotech Shares Soar Premarket On Sale Of R&D Assets

A Massachusetts-based biotech company is stealing the show so far during Tuesday’s premarket hours after it was announced that the company has agreed to sell its pipeline of...

To read the full story on AllPennyStocks.com, click here.

Regeneron Pharmaceuticals (NASDAQ:REGN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024

Click aqui para mais gráficos Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals (NASDAQ:REGN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024

Click aqui para mais gráficos Regeneron Pharmaceuticals.

Notícias Regeneron Pharmaceuticals Inc

Form 144 - Report of proposed sale of securities
Terça, 21 de Maio de 2024 (14 horas atrás) • Edgar (US Regulatory)

Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine
Segunda, 20 de Maio de 2024 (2 dias atrás) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Sexta, 17 de Maio de 2024 (5 dias atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Sexta, 17 de Maio de 2024 (5 dias atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Sexta, 17 de Maio de 2024 (5 dias atrás) • Edgar (US Regulatory)

More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
Sexta, 17 de Maio de 2024 (5 dias atrás) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Quarta, 15 de Maio de 2024 (6 dias atrás) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Terça, 14 de Maio de 2024 (1 semana atrás) • Edgar (US Regulatory)

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
Segunda, 13 de Maio de 2024 (1 semana atrás) • GlobeNewswire Inc.

Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
Quarta, 8 de Maio de 2024 (2 semanas atrás) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Segunda, 6 de Maio de 2024 (2 semanas atrás) • Edgar (US Regulatory)

Regeneron Announces Investor Conference Presentations
Segunda, 6 de Maio de 2024 (2 semanas atrás) • GlobeNewswire Inc.

Mais Notícias de Regeneron Pharmaceuticals Inc

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições